Key Highlights
- NVEC is trading down 34.49% at $67.52 on October 22, with market capitalization of about $360.6 million at the October 21 level.
- Second-quarter revenue fell 8% year over year to $5.83 million, with product sales down 9% and contract R&D revenue up 25%.
- Net income was $3.17 million, or $0.65 per diluted share, against $0.68 a year earlier.
- Six-month revenue rose 36% to $16.9 million, and net income rose 39% to $9.57 million.
- A $1.00 quarterly dividend is payable November 30 to holders of record on November 2.
Why Is NVE Stock Plunging 34% After Its Second-Quarter Report?
NVE (NASDAQ:NVEC) is trading down 34.49% at $67.52 on October 22, following second-quarter fiscal 2027 results released October 21. The shares fell about 28% on the day of the report, so the sell-off has extended into a second session.
What investors may be missing is the sequential picture. Second-quarter revenue of $5.83 million compares with $11.03 million in the June quarter, a calculated decline of roughly 47%, even as the six-month total remains well ahead of last year. No separate company announcement was identified for October 22.
NVE designs and makes spintronic devices, including sensors and couplers used in medical, defense and industrial products.
What Drove the Revenue Decline at NVE?
Revenue slipped 8% from a year earlier to $5.83 million. Product sales fell 9%, while contract research and development revenue rose 25%. According to the earnings call summary, the decline reflected the timing of medical orders and sharply lower defense sales, while distributor sales rose 67%.
Net income was $3.17 million, down 4% from $3.31 million, and diluted EPS was $0.65 versus $0.68. The company ended the quarter with about $3.97 million in cash and cash equivalents, up from $1.71 million at March 31.
Calculated from those figures, net income equaled about 54% of revenue in the quarter, a margin that shows how profitable the model remains even on a smaller revenue base. Operating leverage cuts both ways, however, since a revenue shortfall of this size reaches earnings quickly.
How Does the First Half Compare, and What Is the Dividend?
For the six months, revenue rose 36% to $16.9 million and net income rose 39% to $9.57 million, or $1.97 per diluted share. The first quarter of the year carried unusually strong results, with revenue of $11.03 million and EPS of $1.32.
The board declared a quarterly cash dividend of $1.00 per share, payable November 30 to shareholders of record on November 2. Before the decline, the trailing price-to-earnings ratio was about 20.2 and market capitalization was near $360.6 million.
The call summary indicates management expects second-half revenue to match the first half. On the $16.9 million first-half total, that implies an average of about $8.45 million per quarter, calculated, well above the latest quarter's $5.83 million.
What to Watch After the Two-Day Slide in NVE Shares
The next test is whether quarterly revenue rebounds toward the roughly $8.45 million average implied by second-half expectations, and whether defense and medical orders recover from the timing shortfalls cited. Distributor sales growth of 67% and contract research revenue are the offsetting positives. Investors will also track the dividend, set at $1.00 per share, against earnings of $0.65 per share in the latest quarter.






Please wait processing your request...